Abbott Laboratories (ABT)
Abbott Stock Slips After Company Ordered to Pay $495 Million in Baby Formula Case
Shares of Abbott Laboratories (ABT) came under pressure Monday after a jury in St. Louis late Friday ordered the company to pay $495 million in compensation and damages in a lawsuit over the company's specialized formula for premature babies.
Trial Defeat, Resistance Level Drags Abbott Stock
Abbott Laboratories (NYSE:ABT)) is off 3.6% to trade at $101.44 this morning, suffering a drop after its premature infant formula trial ended in the company needing to pay $495 million in damages to those impacted by a possible increase in bowel disease.
10 Beaten-Up Blue Chips With Serious Turnaround Potential
Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.
Abbott Labs (NYSE: ABT ) stock is falling more than 4% after a St. Louis jury found its premature infant baby formula responsible for a potentially fatal bowel disease. As of this writing, ABT stock is trading around the $100 mark.
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday.
Abbott Labs Stock Falls After Baby-Formula Ruling. Reckitt Benckiser Tumbles Too.
Shares of Abbott Laboratories and U.K.-listed Reckitt Benckiser both drop after a Missouri jury rules against the American healthcare company.
Baby-formula settlement drags Reckitt down after $495 million jury award against Abbott
U.K. consumer-products giant Reckitt saw its share price slump after a jury awarded $495 million in a key baby-formula case.
Reckitt Benckiser shares whacked by US infant formula litigation read-across
Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) shares tumbled 7.5% on Monday morning after a litigation decision in the US against Abbott Laboratories (NYSE:ABT) on Friday, where investors are reading across to the potential impact on the FTSE-listed company. Abbott was ordered to pay almost $500 million over allegations that it hid the risks around its premature infant formula feed, with the case alleging that the formula risks causing a potentially fatal bowel disease.
Abbott must pay $495M in damages after girl develops dangerous disease from premature infant formula
A jury found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $495 million in damages.
Abbott must pay $95 million in premature infant formula trial, jury finds
A jury on Friday found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $95 million in compensatory damages.
Should You Pick Abbott Stock At $105 After A Solid Q2?
Abbott (NYSE: ABT) recently reported its Q2 results, with revenues and earnings exceeding our expectations. The company reported revenue of $10.4 billion and earnings of $1.14 on a per-share and adjusted basis, compared to our estimates of $10.3 billion and $1.10, respectively.
Better Buy: Abbott Laboratories vs. Intuitive Surgical
Healthcare stocks are generally good bets, thanks to a rapidly growing population of older adults in the U.S. and other developed economies. Abbott Laboratories is growing sales at a high-single-digit annual percentage and offers a quarterly dividend.
